Recent years have marked one of the most challenging periods for research and development within the global pharmaceutical and biotechnology (biotech) sectors. Funding headwinds, shrinking candidate pipelines and heightened competition have fundamentally altered the way small and emerging biotechs approach drug discovery and development. Programmes that do secure financing must now advance under tighter timelines and leaner budgets, with little or no room for inefficiency or error. This has led to substantial shifts in contract research and manufacturing approaches and the refinement of outsourcing models to meet ever-changing market needs.
Many biotechs are virtual organisations with no in-house infrastructure, making outsourcing a necessity, not an optional extra. Every discovery and development function, from chemistry to toxicology, pharmacology and DMPK to formulation, must be externally sourced. However, the traditional multi-vendor outsourcing model is showing its limitation in today’s challenging environment. Outsourcing to multiple partners can introduce delays, demand constant coordination across time zones and force already stretched teams to act as de facto programme managers.
Integrated chemistry, manufacturing and controls (CMC) partnerships, which consolidate chemistry, analytical, formulation, quality assurance and regulatory services within the same partner, are increasingly becoming a preferred outsourcing strategy. These partnerships not only reduce the friction associated with multiple contracts but also deliver the speed, consultative expertise and cultural alignment that emerging companies need to thrive in the current competitive and resource-constrained market. In this article, Paul O’Shea, Founder and Chief Scientific Officer at Exemplify BioPharma (a Symeres company), explores the current trends in biotech outsourcing and how integrated CMC partnerships can help accelerate timelines.
The contract research business has faced significant challenges in recent years, driven primarily by external economic and geopolitical factors. The tightening of venture capital has constrained many early-stage preclinical biotechs that rely on external investment to fund development. As a result, numerous projects have been delayed, deprioritised or cancelled.
This contraction in funding has had a direct effect on the outsourcing ecosystem. With fewer funded programmes in the pipeline, the total number of companies seeking outsourcing partnerships has diminished, creating intense competition among contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs).
In this more competitive market, many sponsors now base selection decisions not only on technical capability and quality, but also on a partner’s ability to move quickly, mitigate risk and align culturally – factors that are critical to programme success for early-stage biotechs.
As a result, greater emphasis is being placed on outsourcing strategies that simplify supply chains and support more agile, risk-aware development while also providing a solid cultural fit. Early-stage biotechs often operate with lean teams and virtual business models and have no in-house laboratory or manufacturing capacity. This means every aspect of CMC development must be outsourced, including:
• Active pharmaceutical ingredient (API) synthesis
• Analytical testing
• Formulation development
• Quality assurance
• Regulatory filings
